InvestorsHub Logo
Followers 44
Posts 4776
Boards Moderated 0
Alias Born 06/20/2007

Re: None

Wednesday, 12/10/2014 12:36:07 PM

Wednesday, December 10, 2014 12:36:07 PM

Post# of 50662
Big news for MCET today!

"We are very excited about this novel, enabling antibody-drug conjugate technology that we intend to use for the targeted delivery of MCT-485 as well as other drugs", said W. Gerald Newmin, Chairman and Chief Executive Officer of MultiCell Technologies. "We also plan to explore other therapeutic indications, other drug combinations, and to aggressively seek partnerships with larger pharmaceutical and biotechnology companies who are interested in using ADC technology to help facilitate the targeted delivery of their drugs", stated Mr. Newmin.